BMD42-2910, a Novel Benzoxazole Derivative, Shows a Potent Anti-prion Activity and Prolongs the Mean Survival in an Animal Model of Prion Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyeon, Jae Wook | - |
dc.contributor.author | Noh, Ran | - |
dc.contributor.author | Choi, Jiwon | - |
dc.contributor.author | Lee, Sol Moe | - |
dc.contributor.author | Lee, Yeong Seon | - |
dc.contributor.author | An, Seong Soo A. | - |
dc.contributor.author | No, Kyoung Tai | - |
dc.contributor.author | Lee, Jeongmin | - |
dc.date.available | 2020-04-06T06:39:07Z | - |
dc.date.created | 2020-04-02 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 1226-2560 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26143 | - |
dc.description.abstract | Prion diseases are a group of neurodegenerative and fatal central nervous system disorders. The pathogenic mechanism involves the conversion of cellular priori protein (PrPC) to an altered scrapie isoform (PrPSc), which accumulates in amyloid deposits in the brain. However, no therapeutic drugs have demonstrated efficacy in clinical trials. We previously reported that BMD42-29, a synthetic compound discovered in silico, is a novel anti-prion compound that inhibits the conversion of PrPC to protease K (PK)-resistant PrPSc fragments (PrPres). In the present study. 14 derivatives of BMD42-29 were obtained from BMD42-29 by modifying in the side chain by in silico feedback, with the aim to determine whether they improve anti-priori activity. These derivatives were assessed in a PrPSc-infected cell model and some derivatives were further tested using real time-quaking induced conversion (RT-QuIC). Among them, BMD42-2910 showed high anti-prion activity at low concentrations in vitro and also no toxic effects in a mouse model. Interestingly; abundant PrPres was reduced in brains of mice infected with prion strain when treated with BMD42-2910, and the mice survived longer than control mice and even that treated with BMD42-29. Finally, high binding affinity was predicted in the virtual binding sites (Asn159, Gln 160, Lys194, and Glu196) when PIPC was combined with BMD-42-2910. Our findings showed that BMD42-2910 sufficiently reduces PrPres generation in vitro and in vivo and may be a promising novel anti-prion compound. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC BRAIN & NEURAL SCIENCE, KOREAN SOC NEURODEGENERATIVE DISEASE | - |
dc.relation.isPartOf | EXPERIMENTAL NEUROBIOLOGY | - |
dc.subject | CREUTZFELDT-JAKOB-DISEASE | - |
dc.subject | CELL-CULTURE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | IN-SILICO | - |
dc.subject | PROTEIN | - |
dc.subject | SCRAPIE | - |
dc.subject | IDENTIFICATION | - |
dc.subject | THERAPEUTICS | - |
dc.subject | INHIBITION | - |
dc.subject | QUINACRINE | - |
dc.title | BMD42-2910, a Novel Benzoxazole Derivative, Shows a Potent Anti-prion Activity and Prolongs the Mean Survival in an Animal Model of Prion Disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000518850600008 | - |
dc.identifier.doi | 10.5607/en.2020.29.1.93 | - |
dc.identifier.bibliographicCitation | EXPERIMENTAL NEUROBIOLOGY, v.29, no.1, pp.93 - 105 | - |
dc.identifier.kciid | ART002564081 | - |
dc.identifier.scopusid | 2-s2.0-85082419076 | - |
dc.citation.endPage | 105 | - |
dc.citation.startPage | 93 | - |
dc.citation.title | EXPERIMENTAL NEUROBIOLOGY | - |
dc.citation.volume | 29 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | An, Seong Soo A. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Transmissible spongiform encephalopathy | - |
dc.subject.keywordAuthor | Priori protein | - |
dc.subject.keywordAuthor | Anti-prion | - |
dc.subject.keywordAuthor | Derivatives | - |
dc.subject.keywordAuthor | In silico | - |
dc.subject.keywordPlus | CREUTZFELDT-JAKOB-DISEASE | - |
dc.subject.keywordPlus | CELL-CULTURE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | IN-SILICO | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | SCRAPIE | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | THERAPEUTICS | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | QUINACRINE | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.